THERAPY OF THE POLYCYTHEMIA VERA WITH RUXOLITINIB

Currently, methods of therapeutic the treatment of polycythemia vera (PV) are: prophylaxis of thrombotic complications with acetylsalicylic acid; erythrocytapheresis; cytoreductive therapy; treatment of thrombotic complications; therapy in special conditions (pregnancy, surgery). The first line of the treatment at a young age is interferon a, in the older age group is hydroxycarbamide. In 15-25% of cases, these drugs have low efficiency and poor tolerance. The transition to another line is indicated if the therapy is ineffective or patient is intolerant of the therapy. Results of clinical trials have proved the effectiveness of ruxolitinib, JAK2 inhibitor, in the management of splenomegaly and constitutional symptoms in patients with primary myelofibrosis and PV. A review of the literature and a description of the clinical case of the effective treatment of the PV patient ruxolitinib is presented.